The nation of Zimbabwe has rejected a major US healthcare agreement valued at 367 million US dollars (£272m) over five years over the United States' insistence on confidential information.
The decision became public following a official document dated December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the agreement was "skewed".
A government spokesperson has since stated that the United States was requesting genetic material for scientific study and profit but was not willing to share the benefits from future vaccines.
"We must now begin the difficult and regrettable process of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for continued negotiations to reach a deal suitable to all parties so the country's vital HIV treatment initiative can be sustained.
Wider Context
This rejection comes after a comparable case in Kenya, where a court halted a similar health funding agreement following legal challenges were raised about the safety of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had overseen aid for the American government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral deals to boost transparency and accountability.
As per reports, Sixteen African countries have so far signed similar agreements, representing over $18.3bn in committed funds.
Details of the Rejected Deal
This assistance for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership might have yielded extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving HIV treatment via American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to share its biological resources and data for a long time, without any corresponding guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," his statement read.
"Effectively, our nation would supply the raw materials for medical research without any certainty that the final treatments would be accessible to our people if a new disease outbreak emerge."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its push of bilateral health agreements were undermining systems already established via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to deal with future pandemics.
"This system is intended to ensure that when a country contributes its information, the resulting advantages – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the resources to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," he added.
"We encourage further dialogue with our US partners on how subsequent collaboration could be designed in a manner that honours the sovereignty and dignity of both nations."
Medical Community Response
Medical experts said it acknowledged the government's concerns, but urged that talks need to persist given that a large portion of the country's HIV programmes relied on foreign aid.
"If specific concerns exist, such as those involving data governance or agreement terms, these can often be addressed via technical clarification and mutually agreed protections," it said.
This impasse underscores the continuing debate between receiving crucial international aid and protecting national sovereignty in an increasingly data-driven world.